No, I’m not aiming for any Betty Grable pin up fame, for those of you old enough to know who she was. This is just to show you the new site I found for my Dexcom G6 CGM sensor. My usual, as I know it is for many of you, is my arm. But, I decided maybe it was time to give my arm a rest. I only use my left arm because I sleep on my right side.

Dexcom is only approved in the US for wear on your abdomen. That’s because when they applied for FDA approval, that was the only site they tested it on. But we know you can wear it many different places and it will work just as well. In Europe Dexcom has a CE mark for wearing it on several different sites.

So, I watched this video (Best Sites for Dexcom G6 Sensor Placement) made by an entertaining German who puts out videos at Type One Talks on YouTube, and thought, what the heck, there’s plenty of fat down there, let me give my thigh a try. And, I couldn’t be more pleased.

I totally forget I’m wearing it, it doesn’t bump into anything that could dislodge it and it works just as well (accuracy-wise) best I can figure, as wearing it on my arm or abdomen.

My one caution is, be mindful when wiping yourself dry from the shower or bath. One unthoughtful towel swipe and that could be the end of your sensor session.

Dexcom cover to prevent compression lows above

I don’t know why, but I’m convinced Dexcom doesn’t want you to know about compression lows. I have no idea why you never hear about them. Did you even know there was such a thing? Likely not, proving my point.

Compression lows happen when pressure is applied to the CGM sensor on your body. Most often this happens during sleep when you roll over on it, especially if you wear it on your arm, as so many of us do.

Here’s a fuller explanation of what a compression low is and why it happens. This is written by a parent of a child with type 1 diabetes. These explanations are much easier to find from those of us living with diabetes, than the manufacturers of our CGMs.

Compression lows also happen during the day. If I’m wearing my CGM on my arm, I’ll notice all of a sudden I drop like 20 points for no reason. It takes me a minute or two to realize it’s not a true drop, but the CGM on my arm is pressing against the side of my armchair, or the side of the bus I may be seated on. Move myself away from the source of pressure, and voila, my blood sugar reading rises, once again reflecting reality.

Here’s my compression low the other night while I was sleeping. Can you spot it? Pretty easy.

This is why I keep my iPhone (where I see my Dexcom readings) in my living room and not my bedroom, so these fake lows don’t wake me up in the middle of the night.

Trust me, I’m not telling you to do this. I know my body well enough after living with type 1 for five decades, and I make sure that before I go to sleep I’m at a safe number, even if I have to stay up to 2 am to make sure, which I do.

The only thing I do want you to do is to know about compression lows. Because if you don’t, it’s possible you’ll treat them, and then curse your blood sugar (and yourself) when it goes unnecessarily high. And, you know, that’s just another kick in the head living with diabetes when we already have enough.

I wrote about producer (and T1Der) Lisa Hepner’s new documentary, The Human Trial, when it premiered last month. Yesterday The NY Times ran this beautiful article. I’m posting it below if you can’t use the link.

A documentary captures the desperation and frustration of Type 1 diabetes patients in a clinical trial.

Published Aug. 9, 2022Updated Aug. 10, 2022

Lisa Hepner produced and directed the documentary “The Human Trial” with her husband, Guy Mossman, about people taking part in a clinical trial to treat Type 1 diabetes.Alex Welsh for The New York Times

In the three decades since she was first diagnosed with Type 1 diabetes, Lisa Hepner has clung to a vague promise she often heard from doctors convinced medical science was on the cusp of making her body whole again. “Stay strong,” they would say. “A cure is just five years away.”

But the cure has yet to arrive, and Ms. Hepner, 51, a filmmaker from Los Angeles, remains hobbled by her body’s inability to make insulin, the sugar-regulating hormone produced by the pancreas. “I might look fine to you,” she said, “but I feel crappy 70 percent of the time.”

Staying healthy can be exhausting for many of the 37 million Americans with some form of diabetes. There’s the round-the-clock monitoring of sugar levels; the constant, life-sustaining insulin injections; and the potential threats from diabetes’ diabolical complications: heart disease, blindness, kidney damage and the possibility of losing a gangrenous limb to amputation.

“‘The cure is five years away’ has become a joke in the diabetes community,” Ms. Hepner said. “If it’s so close, then what’s taking so long? And in the meantime, millions of us have died.”

That attenuated sense of hope drove Ms. Hepner to spend nearly a decade following the fortunes of ViaCyte, a small San Diego biotech company working to create what would essentially be an artificial pancreas. If successful, its stem-cell-derived therapy would eliminate the pin-pricks and insulin injections that circumscribe the lives of the 1.5 million Americans with Type 1 diabetes. Vertex Pharmaceuticals, a Boston biotech company developing a similar therapy, has already made significant headway.

Since its theatrical debut in June, “The Human Trial,” the documentary she produced with her husband, Guy Mossman, has electrified the diabetes community, especially those with Type 1, a disease that the uninitiated often conflate with the more common Type 2.

Unlike Type 2, which tends to emerge slowly in adulthood and can sometimes be reversed early on with exercise and dietary changes, Type 1 is an autoimmune disease that often strikes without warning in childhood or adolescence.

Type 1 is also far less prevalent, affecting roughly 10 percent of those with diabetes. A pancreas transplant can cure the disease, but donated organs are in short supply and the surgery carries substantial risks. In most years, only a thousand transplants are done in the United States. To ensure the body does not reject the implanted pancreas, recipients must take immunosuppressant drugs all their lives, making them more susceptible to infections.

Therapies developed from human embryonic stem cells, many experts say, offer the best hope for a lasting cure. “The Human Trial” offers a rare glimpse into the complexities and challenges of developing new therapies — both for the patients who volunteer for the grueling clinical trials required by the Food and Drug Administration, and for the ViaCyte executives constantly scrambling to raise the money needed to bring a new drug to market. These days, the average cost, including the many failed trials along the way, is a billion dollars.

At a time when the soaring price of insulin and other life-sustaining drugs has tarnished public perceptions of the pharmaceutical industry, the film is also noteworthy for its admiring portrayal of a biotech company whose executives and employees appear genuinely committed to helping humanity. (Limiting the cost of insulin remains politically volatile. On Sunday, during a marathon vote on the Democrats’ climate and health bill, Republicans forced the removal of a provision with a $35 cap on insulin prices for patients with private insurance, though the cap remained in place for Medicare patients.)

“The Human Trial,” which can also be viewed online, has become a rallying cry for Type 1 patients, many of whom believe only greater visibility can unleash the research dollars needed to find a cure.

Those who have seen the film have also been fortified by seeing their own struggles and dashed hopes reflected in the journeys of the film’s two main subjects, Greg Romero and Maren Badger, who became among the first patients to have the experimental cell pouches implanted under their skin.

The despair that drives them to become human guinea pigs can be hard to watch. Mr. Romero — whose father also had the disease, went blind before he was 30 and then died prematurely — confronts his own failing vision while grappling with the pain of diabetes-related nerve damage. “I hate insulin needles, I hate the smell of insulin. I just want this disease to go away,” Mr. Romero, 48, says numbly at one point in the film.

Type 1 can leave patients feeling alienated and alone, in part because of flawed assumptions about the disease. Tim Hone, 30, a medical writer in New York who has been living with Type 1 since he was 15, said friends and acquaintances sometimes suggested that he was responsible for causing his illness. “I’ve had people scold me and say that if I went on a diet and stopped eating Snickers bars I could reverse my disease,” Mr. Hone said.

The stigma often drives people with Type 1 to hide the disease. In his quest to feel “normal” at college, Todd Boudreaux said, he avoided telling friends about his illness, a decision that could have had dangerous ramifications in the event of a seizure brought on by low blood sugar levels.

“I didn’t want to be defined by my illness, and I didn’t want to be seen as weak, but having Type 1 does make you different and it’s important that everyone around knows so they can help if you have severe low blood sugar,” said Mr. Boudreaux, 35, who lives in Monterey, Calif., and works for the nonprofit group Beyond Type 1.

Ms. Hepner, too, has spent much of her life downplaying the disease, even with her husband, Mr. Mossman. She recalled his confusion early in their relationship when he awoke to find her discombobulated and drenched in sweat, the result of hypoglycemia, or low blood sugar. The more Mr. Mossman, a cinematographer, learned about the disease, the more he pressed her to make the film.

For years, Ms. Hepner stood her ground, worried about drawing unwanted attention to her health. “It’s a competitive world out there and I just didn’t want people to think, ‘Oh, she’s not thinking straight because her blood sugar is high,’” she said.

But over time, the ubiquity of pink-ribbon breast cancer awareness campaigns and highly publicized efforts to cure Alzheimer’s made Ms. Hepner realize her filmmaking skills could change public perceptions of Type 1, a disease that is nearly invisible, in part because many people who have it do not look sick.

She hopes to change other misperceptions, including the notion that diabetes is a relatively inconsequential and “manageable” illness, one that has been popularized by Big Pharma’s feel-good drug television commercials that feature self-assured patients playing tennis and basketball and piloting hot air balloons.

In fact, the industry spends a fraction of its research dollars on finding a cure, with the rest directed toward developing medications and devices that make it easier to live with the disease, according to the Juvenile Diabetes Cure Alliance.

The payoff from those investments is undeniable. For those who can afford them, continuous glucose-monitoring devices can obviate the need for self-administered finger-prick testing, and the machines can be paired with iPhone-size insulin pumps that eliminate much of the guesswork over dosing.

Ms. Hepner has profound appreciation for the wonders of insulin: At one point in the film she pays homage to its inventor, Frederick Banting, during a visit to his home in Canada. But she notes that insulin-dependent diabetes is no picnic. Many people without insurance cannot afford the thousands of dollars it costs annually for the drug, forcing some to skimp and ration. And a miscalculated or ill-timed dose can lead to seizures, unconsciousness and even death. Even with all the advances in care, only about 20 percent of adults with Type 1 are able to maintain healthy blood sugar levels, according to a 2019 study. On one occasion, Ms. Hepner woke up in the I.C.U. after her insulin pump failed.

“We need to stop trying to normalize this disease because, let’s face it, having diabetes isn’t normal,” she said. “It’s the other pandemic, one that killed 6.7 million people last year around the world.”

Despite her frustrations, it would be inaccurate to describe Mr. Hepner and her film as pessimistic. At the risk of giving away too much, “The Human Trial” ends on a hopeful note. And despite a number of near-brushes with bankruptcy, ViaCyte succeeded in gaining the funding to keep the laboratory lights burning.

Then there is more recent news that did not make it into the film. Last month, ViaCyte was acquired by Vertex, the competing biotech company that has been developing its own stem-cell treatment. That treatment has shown early success, and last year the company announced that a retired postal worker who took part in clinical trials had been cured of Type 1 diabetes.

After almost a lifetime of hearing a cure was just around the corner, Dr. Aaron Kowalski, chief executive of the JDRF (Juvenile Diabetes Research Foundation), the world’s biggest funder of Type 1 research, counts himself as an optimist. A dozen more drug companies are pursuing a cure than a decade ago, he said, and the organization this year plans to spend $100 million on cure research. “It’s not a matter of if this will happen, it’s a matter of when,” said Dr. Kowalski, who is a scientist and has had the disease since childhood, as has a younger brother. “Our job is to make sure it happens faster.”

Until that day, he added, people with diabetes, both Type 1 and Type 2, could use a little empathy and understanding.

This was my blood sugar overnight the other night. Beautiful. Oh, how I wish I could wake up to see this each morning. Yet, this is not usually the case. Some mornings it’s rising like a torpedo, and it could start at 3 or 4 am if that’s when I first awaken during the night.

There is no cause for this beautiful line. It is food, insulin, exercise, mood, stress level, and who knows what else all coming together to create it. Since I eat and exercise similarly, it should look like this every night. But it doesn’t. All to say, you cannot “control” blood sugar.

Still, I thought it pretty enough to post.

Seems as though we’ve been hearing about it forever, but it looks like capping insulin at $35/month is about to become true for people on Medicare. The Democrats budget reconciliation package passed the Senate and is off to the Democratic-controlled House for approval.

The bill empowers Medicare to negotiate prices for certain costly medications including insulin. The bill also redesigns Medicare’s Part D drug plans so seniors wouldn’t pay more than $2,000/year for medications bought at the pharmacy. For more details, check here.

Unfortunately, although Democrats put into the bill a cap on insulin at $35/month for those on private insurance as well, Republicans took it out of the bill. For more details on the bill, you can take a look at “What’s in the Manchin-Schumer deal on climate, health care and taxes.”

Now that it’s been about a year or so that two new glucagon emergency delivery systems have graced pharmacy shelves (Baqsimi and Gvoke HypoPen), Lilly’s familiar orange Glucagon Emergency kit has gone the way of black and white TVs and record players. Kaput.

Remarkably, in 50 years with type 1 diabetes, I have never used a glucagon rescue product. Somehow, gratefully, I’ve always been able to catch my descending lows while I can still chew and swallow. That said, it’s nice to know we have much easier rescue products should I, or you, ever need one.

Still, it’s historic to say goodbye to a diabetes product that’s been around for so long. And, that’s the good news. More has progressed in the last decade in medicine and devices than the 40 years before it. And for that, I’m eternally grateful.

diaTribe carries the full story, “As Glucagon Options Expand, Lilly Discontinues Emergency Kit.”